CGTX
Cognition Therapeutics Inc
$1.08
+0.01 (+0.93%)
At close · Jul 7
Market Cap
$96.66M
Shares
89,498,015
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.08
Open$1.05
Day$1.01–1.13
52W$0.43–3.83
Avg vol 30d1.9M
Short int7.5M · 8.4% float · 5.8d
Short vol56%
Last earningsMay 7, 2026
DataOct 2021–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−12%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−27%
trailing
YTD return
−20%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 75 funds reported for Jun 30 · net +6.7K sh shares
Insider flow
Accumulating
Net +$32.5K over 90 days · 0% sells
Short interest
Rising
8.39% of float · ▲ +16.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
75 holders — mid 3-yr range
Squeeze score
81
high risk · 0–100
Fundamentals
EPS growth
+63%
Y/Y
Free cash flow
$-24.6M
Balance sheet
$36.8M
net cash
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
13.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 7, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 75 funds reported for Jun 30 · net +6.7K sh shares
Insider flow
Accumulating
Net +$32.5K over 90 days · 0% sells
Short interest
Rising
8.39% of float · ▲ +16.9% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
75 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 19%
52-wk high $4
vs 200-day avg -19%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGTX
this stock
Cognition Therapeutics Inc
|
$96.66M | -20.0% | — | — | 8.4% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGTX | -0.9% | -16.3% | -26.5% | -6.1% | -20.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -1.8% | -17.7% | -34.1% | -6.2% | -29.7% |